FRESCO-2: A Global Phase 3 Multiregional Clinical Trial Evaluating the Efficacy and Safety of Fruquintinib in Patients With Refractory Metastatic Colorectal Cancer

Arvind Dasari, MD, MS, presents data from the FRESCO-2 clinical trial evaluating fruquintinib in patients with refractory metastatic colorectal cancer, and provides insights on the clinical implications of the results.

Related Keywords

China ,Australia ,Arvind Dasari , ,Global Phase ,Clinical Trial Evaluating ,Patients With Refractory Metastatic Colorectal ,Partnership With ,Colorectal Cancer ,Refractory Metastatic Colorectal Cancer ,Metastatic Colorectal Cancer ,Fresco 2 ,Fresco 2 Trial ,Fresco 2 Study ,Fruquintinib ,Clinical Trial ,Vegf ,Overall Survival ,